尼安德特人OAS1异构体保护欧洲血统人群抵抗COVID-19易感性和严重性
在504人中测量OAS1水平,非感染状态下较高的血浆OAS1水平与COVID-19易感性和严重性降低相关。进一步分析提示欧洲血统个体中的尼安德特人OAS1异构体提供此保护。
要点
- OAS1水平每升高1个标准差,COVID-19死亡或通气的OR=0.54,住院OR=0.61,易感性OR=0.78。
- 非感染状态下血浆OAS1水平较高与COVID-19易感性和严重性降低相关。
- 欧洲血统个体中的尼安德特人OAS1异构体可能提供保护作用。
核心结论
- MR和病例对照研究证据支持OAS1在COVID-19不良结局中具有保护作用。
研究设计与样本
- 在504名个体中测量OAS1水平,进行病例对照分析。
主要发现
- OAS1水平每升高1个标准差,与COVID-19死亡或通气风险降低相关(OR=0.54,P=7×10-8)。
- OAS1水平每升高1个标准差,与COVID-19住院风险降低相关(OR=0.61,P=8×10-8)。
- OAS1水平每升高1个标准差,与COVID-19易感性降低相关(OR=0.78,P=8×10-6)。
- 非感染状态下较高的血浆OAS1水平与COVID-19易感性和严重性降低相关。
临床怎么用
- 可优先考虑开发提高OAS1水平的现有药物用于COVID-19治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To identify circulating proteins influencing Coronavirus Disease 2019 (COVID-19) susceptibility and severity, we undertook a two-sample Mendelian randomization (MR) study, rapidly scanning hundreds of circulating proteins while reducing bias due to reverse causation and confounding. In up to 14,134 cases and 1.2 million controls, we found that an s.d. increase in OAS1 levels was associated with reduced COVID-19 death or ventilation (odds ratio (OR) = 0.54, P = 7 × 10-8), hospitalization (OR = 0.61, P = 8 × 10-8) and susceptibility (OR = 0.78, P = 8 × 10-6). Measuring OAS1 levels in 504 individuals, we found that higher plasma OAS1 levels in a non-infectious state were associated with reduced COVID-19 susceptibility and severity. Further analyses suggested that a Neanderthal isoform of OAS1 in individuals of European ancestry affords this protection. Thus, evidence from MR and a case-control study support a protective role for OAS1 in COVID-19 adverse outcomes. Available pharmacological agents that increase OAS1 levels could be prioritized for drug development.
引用
- Zhou S, Butler-Laporte G, Nakanishi T, et al. A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. Nat Med. 2021. PMID: 33633408. doi:10.1038/s41591-021-01281-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。